双膦酸盐相关性颌骨坏死发病机制的研究进展

摘要/Abstract

摘要： 双膦酸盐相关性颌骨坏死(bisphosphonaterelated osteonecrosis of the jaw，BRONJ) 是患者长期使用双膦酸盐药物引起的严重不良反应。其主要症状包括软组织破溃、骨面外露、坏死区流脓、局灶牙齿松动等。目前的临床治疗以局部死骨摘除等对症处理为主，由于病因学机制尚不明确，缺乏相应的对因治疗。学者们提出不同的病因学机制，包括颌骨代谢失衡、抑制血管生成、微生物感染、免疫功能紊乱、软组织毒性等。现将近年来对该病的发病机制的研究进展作一综述。

关键词: 双膦酸盐相关性颌骨坏死, 破骨细胞, 骨代谢

Abstract: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious adverse reaction caused by long-term use of bisphosphonate in patients. Its main symptoms include soft tissue rupture, bone surface exposure, necrotic area flow pus, focal tooth loosening and so on. Because of the unclear etiological mechanism and lack of corresponding etiological treatment, the current clinical treatment is mainly local dead bone removal and other symptomatic treatment. Scholars have proposed different etiological mechanisms, including imbalance of the bone turnover of the jaw, inhibition of angiogenesis, microbial infection, immune dysfunction, soft tissue toxicity and so on. The recent research progress in the pathogenesis of the disease is reviewed in this paper.

Key words: BRONJ, osteoclast, bone metabolism

中图分类号:

R782.32

罗号刘忠龙李晓光孟箭何悦. 双膦酸盐相关性颌骨坏死发病机制的研究进展[J]. 口腔医学, 2021, 41(4): 373-376.

参考文献 44

[1]	Marx RE.Pamidronate(Aredia) and zoledronate(Zometa) induced avascular necrosis of the jaws: a growing epidemic[J].J Oral Maxillofac Surg, 2003, 61(9):1115-1117
[2]	Ruggiero SL, Dodson TB, Assael LA, et al.American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw-2009 update[J].Aust Endod, 2009, 35(3):119-130
[3]	Fliefel R, Tr?ltzsch M, Kühnisch J, et al.Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw(BRONJ)with characterization of patients:a systematic review[J].Int J Oral Maxillofac Surg, 2015, 44(5):568-585
[4]	Wehrhan F, Amann K, M?bius P, et al.BRONJ-related jaw bone is associated with increased Dlx-5 and suppressed osteopontin-implication in the site-specific alteration of angiogenesis and bone turnover by bisphosphonates[J].Clin Oral Investig, 2015, 19(6):1289-1298
[5]	Marx R E.A decade of bisphosphonate bone complications: what it has taught us about bone physiology[J].Int J Oral Maxillofac Implants, 2014, 29(2):e247-e258
[6]	Zafar S, Coates DE, Cullinan MP, et al.Zoledronic acid and geranylgeraniol regulate cellular behaviour and angiogenic gene expression in human gingival fibroblasts[J].Journal of Oral Pathology&Medicine, 2014, 43(9):711-721
[7]	Zafar S, Coates DE, Cullinan MP, et al.Effects of zoledronic acid and geranylgeraniol on the cellular behaviour and gene expression of primary human alveolar osteoblasts[J].Clinical Oral Investigations, 2016, 20(8):2023-2035
[8]	Ikebe, Tetsuro.Pathophysiology of BRONJ:Drug-related osteoclastic disease of the jaw[J].Oral Science International, 2013, 10(1):1-8
[9]	SJ.McTaggartIsoprenylated proteins[J].Cellular&Molecular Life Sciences Cmls, 2006, 63(3):255-267
[10]	Fontalis A, Eustathios K, Prousali E, et al.Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis[J].Expert Opinion on Drug Safety, 2018, 17(4):413-428
[11]	Lewiecki EM.New and emerging concepts in the use of denosumab for the treatment of osteoporosis[J].Ther Adv Musculoskelet Dis, 2018; 10(11):209-223.[J].Ther Adv Musculoskelet Dis, 2018, 10(11):209-223
[12]	Cao X.RANKL-RANK signaling regulates osteoblast differentiation and bone formation[J].Bone Research, 2018; 6(35):426-427.[J].Bone Research, 2018, 6(35):426-427
[13]	Martin TJ, Sims NA.RANKLOPG;Critical role in bone physiology[J].Rev Endocr Metab Disord, 2015, 16(2):131-139
[14]	Ohe JY, Kwon YD, Lee HW.Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts[J].Clin Oral Investig, 2012, 16(4):1153-1159
[15]	Tipton DA, Seshul BA, Dabbous MKh.Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis:RANKL,osteoprotegerin and interleukin-6[J].J Periodontal Res, 2011, 46(1):39-47
[16]	Yang H, Pan H, Yu F, et al.A novel model of bisphosphonaterelated osteonecrosis of the jaw in rats[J].Int J Clin Exp Pathol, 2015; 8(5):5161-5167.[J].Int J Clin Exp Pathol, 2015, 8(5):5161-5167
[17]	Tsubaki M, Satou T, Itoh T, et al.Bisphosphonate-and statin-induced enhancement of OPG expression and inhibition of CD9,M-CSF,and RANKL expressions via inhibition of the RasMEKERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2[J].Mol Cell Endocrinol, 2012, 361(1-2):219-231
[18]	Patntirapong S, Singhatanadgit W, Chanruangvanit C, et al.Zoledronic acid suppresses mineralization through direct cytotoxicity and osteoblast differentiation inhibition[J].J Oral Pathol Med, 2012, 41(9):713-720
[19]	Cackowski FC, Roodman GD.Perspective on the osteoclast: an angiogenic cell?[J].Ann NY Acad Sci, 2007, 1117(none):12-25
[20]	Stresing V, Fournier P G, Bellahcene A, et al.Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase[J].Bone, 2011; 48(2):259-266.[J].Bone, 2011, 48(2):259-266
[21]	Pabst AM, Ziebart T, Ackermann M.Bisphos-phonates' ?antiangiogenic?potency?in?the?development?of? bisphosphonate-associated? osteonecrosis? of? the?jaws:?influence?on?microvessel?sprouting?in?an in vivo 3D? Matrigel? assay[J].Clin? Oral? Invest, 2014; 18(3):1015-1022.[J].Clin? Oral? Invest, 2014, 18(3):1015-1022
[22]	Xie H, Cui Z, Wang L, et al.PDGF-BB secreted by preosteoclasts induces CD31 hiEmcnhi vessel subtype in coupling osteogenesis[J].Nature Medicine, 2014, 20(11):1270-1278
[23]	Gao SY, Zheng GS, Wang L, et al.Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB[J].PLoS One, 2017, 12(6):e0179248--
[24]	Mücke, Thomas, Koerdt S, et al.The Role of Mylohyoid Flap in the Treatment of Bisphosphonate Related Osteonecrosis of the Jaws[J].Journal of Cranio-Maxillofacial Surgery, 2016, 44(4):369-73
[25]	Sun J, Wen X, Jin F, et al.Bioinformatics analyses of differentially expressed genes associated with bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma[J]. Onco Targets Ther, 2015, 8: 2681-2688.[J].Onco Targets Ther, 2015, 8(none):2681-2688
[26]	Sedghizadeh PP, Yooseph S, Fadrosh DWet al.Metagenomic investigation of microbes and viruses in patients with jaw osteonecrosis associated with bisphosphonate therapy[J].Oral Surg Oral Med Oral Pathol Oral Radiol.2012, 114(6):764-770.[J].Oral Surg Oral Med Oral Pathol Oral Radiol, 2012, 114(6):764-770
[27]	Hinson AM, Smith CW, Siegel ER, et al.Is bisphosphonate-related osteonecrosis of the jaw an infection?A histological and microbiological ten-year summary[J].Int J Dent.2014, 2014:452737.[J].Int J Dent, 2014, 2014(none):452737--
[28]	Nakamura KFukumoto T, Fukui T, et al.A case of bisphosphonate-related osteonecrosis of the jaw with difficulty in treatment[J].Hinyokika Kiyo, 2016, 62(1):39-44
[29]	Bramati A, Girelli S, Farina G, et al.Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases[J].J Bone Miner Metab.2015, 33(1):119-24.[J].J Bone Miner Metab, 2015, 33(1):119-124
[30]	Khan AA, Morrison A, Hanley DA, et al.Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus[J].J Bone Miner Res., 2015, 30(1):3-23
[31]	Kuiper JW, Forster C, Sun C, et al.Zoledronate and pamidronate depress neutrophil functions and survival in mice[J].Br J Pharmacol, 2012; 165(2):532-539.[J].Br J Pharmacol, 2012, 165(2):532-539
[32]	Favot CL, Forster C, Glogauer M.The effect of bisphosphonate therapy on neutrophil function: a potential biomarker[J].Int J Oral MaxilSurg, 2013, 42(5):619-626
[33]	Kalyan S, Wang J, Quabius ES, et al.Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonate-associated osteonecrosis of the jaw[J].J Transl Med, 2015, 13(1):212--
[34]	] Li Y, Xu J, Mao L, et al.Allogeneic mesenchymal stem cell therapy for bisphosphonate-related jaw osteonecrosis in Swine[J].Stem Cells Dev.2013, 22(14):2047-2056.[J].Stem Cells Dev, 2013, 22(14):2047-2056
[35]	Cella L, Oppici A, Arbasi M, et al.Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw[J].Head Face Med.2011, 7:16.[J].Head Face Med, 2011, 7(1):16--
[36]	Kikuiri T, Kim I, Yamaza T, et al.Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice[J].J Bone Miner Res. 2010, 25(7):1668-1679.[J].J Bone Miner Res, 2010, 25(7):1668-1679
[37]	Otto S, Schreyer C, Hafner S, et al.Bisphosphonate-related osteonecrosis of the jaws-characteristics, risk factors, clinical features, localization and impact on oncological treatment[J].J Craniomaxillofac Surg.2012, 40(4):303-309.[J].J Craniomaxillofac Surg, 2012, 40(4):303-309
[38]	Mozzati M, Arata V, Gallesio G.Tooth extraction in osteoporotic patients taking oral bisphosphonates[J].Osteoporos Int. 2013, 24(5):1707-1712.[J]..Osteoporos Int, 2013, 24(5):1707-1712
[39]	He LH, Xiao E, An JG, et al.Role of bone marrow stromal cells in impaired bone repair from BRONJ osseous lesions[J].J Dent Res, 2017, 96(5):539-546
[40]	Mozzati M, Martinasso G, Maggiora M, et al.Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid[J].2013, 17(4):1259-1266.[J].Clinical Oral Investigations, 2013, 17(4):1259-1266
[41]	Basso FG, Turrioni AP, Hebling J.Zoledronic acid decreases gene expression of vascular endothelial growth factor and basic fibroblast growth factor by human epithelial cells[J].Br J Oral Maxillofac Surg, 2013, 51(8):971-978
[42]	Carneiro, Natália Santos, Armada, et al.Evaluation of KGF, EGF, VEGF, bcl-2, IL-6 and ki67 expression in oral epithelium adjacent to bisphosphonate-related osteonecrosis and florid osseous dysplasia: a comparative immunohistochemical study[J].Oral Surg Oral Med Oral Pathol Oral Radiol.2017, 124(6):548-553.[J].Oral Surg Oral Med Oral Pathol Oral Radiol, 2017, 124(6):548-553
[43]	Thomas Z, Frank H, Paul H, et al.Impact of Soft Tissue Pathophysiology in the Development and Maintenance of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ)[J].Dentistry Journal, 2016, 4(4):36--
[44]	] Li M, Yu Y, Shi Y.Decreased Osteogenic Ability of Periodontal Ligament Stem Cells Leading to Impaired Periodontal Tissue Repair in BRONJ Patients.[J].Stem Cells Dev.2020, 29(3):156-168.[J].Stem Cells Dev, 2020, 29(3):156-168